Fast Facts for Board Review

Biologics for Psoriasis

Cutis. 2016 March;97(3)
By
Lindsay C. Strowd, MD
Author and Disclosure Information

As part of our commitment to resident education, Cutis is excited to offer this monthly section with board-relevant, easy-to-review material.

This study material discusses the current US Food and Drug Administration–approved biologic medications for psoriasis and psoriatic arthritis, including the mechanism of action, dosing, and side effects.
PDF Download

 

Review the PDF of the fact sheet on biologics for psoriasis with board-relevant, easy-to-review material. This month's fact sheet discusses the current US Food and Drug Administration–approved biologic medications for psoriasis and psoriatic arthritis, including the mechanism of action, dosing, and side effects.

Practice Questions

1. Which biologic is administered as an intravenous infusion?

a. adalimumab

b. etanercept

c. infliximab

d. secukinumab

e. ustekinumab

Pages

Next Article:

Biologics for Pediatric Psoriasis Patients?

Related Articles

  • Fast Facts for Board Review

    Allergic Contact Dermatitis, Part 4

    Author:
    Laura Doerfler, MD
    William W. Huang, MD, MPH

    As part of our commitment to resident education, Cutis is excited to offer this monthly section with board-relevant, easy-to-review...

  • Fast Facts for Board Review

    Viruses, Part 2: RNA Viruses

    Author:
    Jenna O'Neill, MD

    As part of our commitment to resident education, Cutis is excited to offer this monthly section with board-relevant, easy-to-review...

  • Fast Facts for Board Review

    Genetic Pathways, Part 2

    Author:
    Alyssa Daniel, MD
    Publish date: December 29, 2015

    As part of our commitment to resident education, Cutis is excited to offer this monthly section with board-relevant, easy-to-review...